TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32055862
Drug: Diethylcarbamazine treatment
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine treatment
Study: 32057467
Drug: Nivolumab 240mg
Normalized name: nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 240mg Q2W for 6 infusions and ipilimumab 1mg/kg Q6W for 2 infusions in neoadjuvant setting, followed by nivolumab 480mg Q4W for 9 infusions post-surgery.
Study: 32058557
Drug: gFOLFIRINOX therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: gFOLFIRINOX therapy (fluorouracil 2400 mg/m2 over 46 hours; oxaliplatin 85 mg/m2; irinotecan 180 mg/m2 for UGT1A1 genotype 6/6, 135 mg/m2 for 6/7, or 90 mg/m2 for 7/7; prophylactic peg-filgastrim 6 mg) for 4 cycles before and after surgery.
Study: 32058557
Drug: gFOLFIRINOX therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: gFOLFIRINOX therapy with trastuzumab for ERBB2-positive tumors.
Study: 32058557
Drug: gFOLFIRINOX therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: gFOLFIRINOX therapy (including trastuzumab for ERBB2-positive tumors)
Study: 32058843
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) at recommended doses for expansion (5.4 or 6.4 mg/kg) administered intravenously once every 3 weeks
Study: 32058843
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) at 6.4 mg/kg
Study: 32059719
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (382 patients)
Study: 32059719
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (589 patients, 388 RYGB and 201 SG)
Study: 32059719
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (156 patients left the study without treatment)
Study: 32060053
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg intravenously on day 1 and capecitabine 1000 mg/m²
Study: 32060165
Drug: Intravenous or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous or intramuscular thiamine (100 mg daily for a minimum of 3 days)
Study: 32061453
Drug: Single ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ketamine infusion (0.5 mg/kg)
Study: 32061453
Drug: Repeated ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated ketamine infusions (0.5 mg/kg)
Study: 32062041
Drug: Vedolizumab therapy
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab therapy
Study: 32062172
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for lesions with FFR (≤0.8) and CFR (<2.0)
Study: 32062681
Drug: Lanreotide autogel/depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide autogel/depot (LAN) combined with peptide receptor radionuclide therapy (PRRT)
Study: 32063492
Drug: Enzalutamide (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide (160 mg/d) with ADT and RT (66 Gy)
Study: 32063845
Drug: Mephedrone plus
Normalized name: Mephedrone
DrugBank: Mephedrone (DB13108)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mephedrone plus alcohol (200 mg mephedrone + 0.8 g/kg alcohol)
Study: 32063845
Drug: Mephedrone alone
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mephedrone alone (200 mg mephedrone + placebo alcohol)
Study: 32063845
Drug: Alcohol alone
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol alone (placebo mephedrone + 0.8 g/kg ethanol)
Study: 32064663
Drug: Digital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital treatment augmentation study
Study: 32064766
Drug: ART drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART drug costs
Study: 32065330
Drug: JNJ-4178 (adafosbuvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-4178 (adafosbuvir 800 mg QD, odalasvir 25 mg QD, simeprevir 75 mg QD) for 8 weeks (Cohort 1) or 12 weeks (Cohort 2)
Study: 32065330
Drug: JNJ-4178 (adafosbuvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-4178 (adafosbuvir 800 mg QD, odalasvir 25 mg QD, simeprevir 75 mg QD)
Study: 32065359
Drug: Rosuvastatin 5
Normalized name: rosuvastatin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5 mg/ezetimibe 10 mg once daily
Study: 32065631
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate/emtricitabine 300/200 mg daily for 14 days
Study: 32066540
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg once daily, taken orally, until progression or unacceptable toxicity.
Study: 32067048
Drug: DTaP-IPV-Hib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV-Hib and 13-valent pneumococcal conjugate vaccine (PCV13) concurrently, followed by 23-valent pneumococcal polysaccharide vaccine (PPV23) 2 months later.
Study: 32067679
Drug: Residual PIK3CA
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual PIK3CA mutations in plasma after chemotherapy
Study: 32067683
Drug: chemotherapy-free regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy-free regimens matched to specific molecular alterations
Study: 32067695
Drug: Optimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal treatment of underlying conditions
Study: 32070310
Drug: CPAP oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP oxygen treatment
Study: 32071055
Drug: LPV/r-4:1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r-4:1 (1 month after treatment completion)
Study: 32071418
Drug: Ruxolitinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib therapy in acute srGVHD
Study: 32071418
Drug: Ruxolitinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib therapy in chronic srGVHD
Study: 32071418
Drug: Ruxolitinib therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib therapy in both acute and chronic srGVHD
Study: 32071614
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (control) for 4 months, followed by SSM intervention.
Study: 32072161
Drug: Intravenous fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fish oil (FO) 1 g/kg/d
Study: 32074275
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) at 75 mg/m2 subcutaneously or IV once daily on days 1 to 5 followed by HiDAC (3000 mg/m2) and mitoxantrone (30 mg/m2) once each on days 6 and 10.
Study: 32074275
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) at 50 mg/m2 (dose-limiting toxicities occurred).
Study: 32074275
Drug: Azacitidine (AZA)
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine (AZA) at 37.5 mg/m2 (not specifically reported).
Study: 32074665
Drug: Calcipotriol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) foam applied once daily for ≤4 weeks
Study: 32074665
Drug: Calcipotriol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) foam
Study: 32075470
Drug: Dupilumab, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 signaling, specific dosage and duration not mentioned.
Study: 32075790
Drug: Macrolide antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrolide antibiotics during pregnancy (first trimester)
Study: 32075790
Drug: Macrolide antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrolide antibiotics during pregnancy (any trimester)
Study: 32075790
Drug: Penicillin antibiotics
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin antibiotics during pregnancy
Study: 32076124
Drug: AZD3965 (mono-carboxylase
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3965 (mono-carboxylase transporter 1 inhibitor)
Study: 32076889
Drug: Dotinurad (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotinurad (4 mg) with oxaprozin
Study: 32076889
Drug: Dotinurad (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dotinurad (4 mg) alone
Study: 32077361
Drug: Sequential ('primed')
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential ('primed') decitabine in combination with CLAG-M
Study: 32077361
Drug: Concurrent decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent decitabine in combination with CLAG-M
Study: 32077895
Drug: Trabectedin (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin (1.3 mg/m2 starting dose, 1.5 mg/m2 dose level +1, 1.1 mg/m2 dose level -1) plus radiotherapy (30 Gy, 3 Gy/d for 10 days)
Study: 32077895
Drug: Trabectedin (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin (1.3 mg/m2 starting dose, 1.5 mg/m2 dose level +1, 1.1 mg/m2 dose level -1)
Study: 32078124
Drug: Split first
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split first dose of intravenous daratumumab (16 mg/kg split into two 8 mg/kg doses on Days 1 and 2)
Study: 32078124
Drug: Single first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single first dose of intravenous daratumumab (16 mg/kg)
Study: 32078124
Drug: Split first
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split first dose of intravenous daratumumab
Study: 32078124
Drug: Single first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single first dose of intravenous daratumumab
Study: 32078813
Drug: Cabozantinib (adults
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (adults 60 mg, children <16 years 40 mg)
Study: 32079476
Drug: Modifiable bleeding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modifiable bleeding risk factors (heavy alcohol use, uncontrolled hypertension, concomitant treatment with antiplatelets, NSAIDs, or paracetamol)
Study: 32079702
Drug: ctDNA analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: ctDNA analysis after 2 cycles of chemotherapy (C2)
Study: 32079709
Drug: PARP inhibitors
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitors (olaparib, niraparib, rucaparib)
Study: 32083013
Drug: Adjuvant Immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Immunotherapy
Study: 32084409
Drug: Ad5-DS (adenovirus-mediated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad5-DS (adenovirus-mediated double-suicide gene therapy) injected into pancreatic mass with EUS-guided fine needles, combined with oral 5-fluorocytosine and valganciclovir, and standard dose of intravenous gemcitabine.
Study: 32085891
Drug: Lurbinectedin monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurbinectedin monotherapy, administered intravenously at 3.2 mg/m²
Study: 32086343
Drug: Toripalimab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab (3 mg/kg once every two weeks)
Study: 32086361
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention using the Drug Burden Index (DBI) Calculator
Study: 32086697
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (double-scattered conformal proton therapy) to a mean dose of 54 GyRBE in 1.8 GyRBE/fraction (range 52.2-54 GyRBE)
Study: 32086697
Drug: Proton therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton therapy (double-scattered conformal proton therapy)
Study: 32087152
Drug: Medication refills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication refills at week 4
Study: 32087152
Drug: Medication refills
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication refills at week 72
Study: 32087715
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (50 mg for 10-<25 kg, 87.5 mg for 25-<50 kg)
Study: 32087715
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept (with/without methotrexate and/or low-dose corticosteroids)
Study: 32087733
Drug: PCV +
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCV + PPV23 in all treatment groups
Study: 32088180
Drug: Adjunctive strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive strategies (neuromuscular blockade, prone position, extracorporeal membrane oxygenation, inhaled vasodilators, high-frequency ventilation)
Study: 32088180
Drug: Adjunctive strategies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive strategies
Study: 32088322
Drug: GLS-6150 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS-6150 (4 mg, 3 mg, or 6 mg/vaccination, administered 4 times at 4-week intervals, followed by a 6 mg boost at 24 weeks)
Study: 32088879
Drug: Glycemia overtreatment
Normalized name: Glycerin
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycemia overtreatment (HbA1c < 6.5% with ≥ 2 oral antihyperglycemics or insulin)
Study: 32088879
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure overtreatment (SBP < 120 mmHg or DBP < 65 mmHg with ≥ 2 drugs)
Study: 32088879
Drug: Deintensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deintensification of glycemia treatment
Study: 32088879
Drug: Intensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification of glycemia treatment
Study: 32088879
Drug: Deintensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deintensification of BP treatment
Study: 32088879
Drug: Intensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification of BP treatment
Study: 32089047
Drug: Hyperoxia treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperoxia treatment, specific dosage and duration not mentioned
Study: 32089164
Drug: CCR5 antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: CCR5 antagonists
Study: 32089640
Drug: Ganetespib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib (200 mg/m) and Sirolimus (oral mTOR inhibitor)
Study: 32089871
Drug: Panretinal photocoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panretinal photocoagulation (PRP) and/or intravitreal injections (IVIs) of anti-VEGF
Study: 32091493
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 4 or 6 mg/kg every 8 hours by 1-hour intravenous infusion plus intravenous ampicillin and optional aminoglycoside for 48 hours-14 days
Study: 32091493
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 6 mg/kg every 8 hours
Study: 32091590
Drug: Atropine (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (0.04 mg/kg intravenous)
Study: 32092139
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg/d in combination with cytarabine/daunorubicin induction on days 1 to 7, followed by dasatinib 100 mg/d on days 6 to 26 for 4 courses, and then dasatinib 100 mg/d for 12 months after achieving complete remission.
Study: 32092139
Drug: Dasatinib 100
Normalized name: dasatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dasatinib 100 mg/d
Study: 32093506
Drug: Noninvasive remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noninvasive remote monitoring using a disposable multisensor patch
Study: 32093649
Drug: Gemcitabine/erlotinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/erlotinib treatment with skin rash
Study: 32093649
Drug: Gemcitabine/erlotinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/erlotinib treatment without skin rash
Study: 32093649
Drug: Gemcitabine/erlotinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/erlotinib treatment with skin rash grade ≥ 2
Study: 32093649
Drug: Gemcitabine/erlotinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/erlotinib treatment in patients > 65 years
Study: 32093649
Drug: Gemcitabine/erlotinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/erlotinib treatment
Study: 32094063
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks in 6-week cycles
Study: 32094925
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment for subretinal inflammation
Study: 32313553
Drug: Ready-to-drink SPMC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ready-to-drink SPMC oral solution
Study: 32095161
Drug: Split-dose, low-volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose, low-volume sodium picosulfate, magnesium oxide, and citric acid powder for oral solution
Study: 32095777
Drug: Single intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravitreal injection of aflibercept
Study: 32095919
Drug: 4 MBq/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 MBq/kg dosage group
Study: 32095919
Drug: 2 MBq/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 MBq/kg dosage group
Study: 39630397
Drug: Furosemide administration
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide administration
Study: 32096654
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose monitoring system which wirelessly transmits results to compatible insulin pumps
Study: 32097091
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg and bevacizumab 15 mg/kg given intravenously every 3 weeks (phase II)
Study: 32097119
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (graded repetitive arm supplementary program; GRASP) with no supervision for 2 months.
Study: 32098623
Drug: Oral Ty21a
Normalized name: Salmonella typhi Ty21a live antigen 2000000000 UNT [Vivotif]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Ty21a (4 doses)
Study: 32098874
Drug: Rituximab (RTX),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (RTX), administered in a minimum of two to a maximum of three cycles, specific dosage and duration not detailed.
Study: 32100175
Drug: Propofol administered
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol administered via target controlled infusion (TCI) with EEG-derived bispectral index (BIS) monitoring.
Study: 32100191
Drug: Continuous variable
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous variable of canned and cooked tomato consumption (64 g/day)
Study: 32100191
Drug: 24-h dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-h dietary recall intake of 71 g/day canned and cooked tomato product
Study: 32100192
Drug: Gla-300 (Glargine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gla-300 (Glargine 300 U/mL)
Study: 32100192
Drug: IDeg-100 (Degludec
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDeg-100 (Degludec 100 U/mL)
Study: 32101140
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment strategy including wound care (98.9%), antibiotherapy (77.5%), discontinuation of Vitamin K antagonists (VKA) (70.8%), intravenous sodium thiosulfate (65.2%)
Study: 32101614
Drug: Triple Therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple Therapy (TT group)
Study: 32102167
Drug: 2.67 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.67 g/day agmatine sulfate (AgmaSet)
Study: 32102676
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anesthesia (target-controlled infusion using the Schneider model)
Study: 32102950
Drug: Pembrolizumab-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab-based therapy (alone or in combination with chemotherapy)
Study: 32103260
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg once daily with food
Study: 32104059
Drug: N-methyl-D-aspartate antagonists
Normalized name: N-methyl-D-glucamine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-methyl-D-aspartate antagonists (intravenous ketamine and oral memantine)
Study: 32104962
Drug: Simultaneous acoustic
Normalized name: aconite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous acoustic vibrations and positive expiratory pressure applied to the nasal cavity twice daily over 5 weeks
Study: 32105293
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (HPV-6, -11, -16, and -18) administered via intramuscular injections on days 1 and 2 and then 6 months later.
Study: 32105293
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV vaccine (HPV-6, -11, -16, and -18) administered via intramuscular injections.